Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 in combination therapy for advanced urothelial carcinoma (Ib/II, open-label, multicenter)
CTR20243811Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in urothelial carcinoma (UC), sponsored by Hengrui Therapeutics. Started Nov 2024; status: active.
02
Drugs
SHR-A2102
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on CTR20243811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243811.